title: Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement.
abstract: Here, we report the preliminary results of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) with granulocyte-colony-stimulating factor (G-CSF) mobilized bone marrow grafts without T-cell depletion for 10 patients with refractory non-Hodgkin lymphoma accompanied by bone marrow involvement. Eight patients received a conditioning regimen consisting of high-doses of cytarabine and cyclophosphamide with total body irradiation, whereas two cases were preconditioned with busulfan, thiotepa, and cyclophosphamide. All patients had rapid hematopoietic engraftment with the mean time for neutrophil and platelet recovery being 16.6 days and 19.2 days, respectively. Three cases died within 6 months after transplantation from severe acute graft-versus-host disease, fungal infection, or relapse. The others are currently alive in complete remission at a median follow-up of 60.71 months (range: 44-81 months). The results here suggest that haplo-HSCT might provide an opportunity of myeloablative therapy for refractory lymphoma with marrow infiltration.
authors.affiliation: Department of Hematology, The General Hospital of Air Force, Beijing, China.
authors.forename: Heng-Xiang
authors.initials: HX
authors.lastname: Wang
authors.forename: Hong-Min
authors.initials: HM
authors.lastname: Yan
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Lian-Ning
authors.initials: LN
authors.lastname: Duan
authors.forename: Zhi-Dong
authors.initials: ZD
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Zhu
authors.forename: Mei
authors.initials: M
authors.lastname: Xue
authors.forename: Zi-Kuan
authors.initials: ZK
authors.lastname: Guo
mesh_terms: D000293:Adolescent; D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D019046:Bone Marrow Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D002648:Child; D019008:Drug Resistance, Neoplasm; D005260:Female; D006086:Graft vs Host Disease; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006239:Haplotypes; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006650:Histocompatibility Testing; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D010865:Pilot Projects; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor